{'fraction_non_alphanumeric': 0.02526315789473684, 'fraction_numerical': 0.008421052631578947, 'mean_word_length': 5.8, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anti-inflammatory actions of lipoxins

Efforts to understand and harness the potent anti-inflammatory and immunomodulating properties of the endogenous lipid mediators lipoxin A4 (LXA4), lipoxin B4 (LXB4) and the aspirin-triggered lipoxins, have resulted in a number of patent applications by both academic research groups and pharmaceutical companies. The patents cover the anti-inflammatory properties of lipoxins across a range of diseases with components of inflammation.